Key result
Rivaroxaban plus aspirin fails to alter coagulation or inflammatory biomarkers versus aspirin alone in claudication.
Why the study?
A better understanding of coagulation and inflammatory biomarkers could serve as prognostic indicators and inform clinical decision-making in patients with peripheral artery disease and intermittent claudication treated with rivaroxaban plus aspirin versus aspirin alone.
Does rivaroxaban plus aspirin alter coagulation and inflammatory biomarkers compared to aspirin alone in patients with intermittent claudication?
RCT (n=36)
open-label
electronic form through our CRF registered on the Redcap platform
Yes
Does rivaroxaban plus aspirin alter coagulation and inflammatory biomarkers compared to aspirin alone in patients with intermittent claudication?
The addition of rivaroxaban to aspirin does not significantly alter conventional coagulation or inflammatory biomarkers at 24 weeks in patients with intermittent claudication, suggesting these biomarkers may not be useful for monitoring this therapy.
Answers are grounded in this paper and cite their sources.
Biomarker monitoring of rivaroxaban plus aspirin appears uninformative in intermittent claudication; challenges their utility while leaving walking benefit mechanism open.
IntroductionA prospective, randomized, multicenter study compared rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily against aspirin 100 mg once daily alone in patients with peripheral artery disease and intermittent claudication. The study demonstrated that rivaroxaban plus aspirin improved total walking distance. A better comprehension of coagulation and inflammatory biomarkers could serve as a prognostic indicator and inform clinical decision-making.MethodsThis is a subsequent biomarker analysis, including 36 patients from both arms and plasma from healthy controls. We used human plasma for comparison purposes of the baseline biomarkers for normality testing. Plasma levels of biomarkers relating to coagulation activation (DD, vWF, thrombin generation potential (TGP), fibrinolysis (PAI-1, TAFI) and inflammation (CRP) were assessed at baseline (day 0) and measured after 24 weeks.ResultsSamples from 16 patients allocated to the aspirin plus rivaroxaban group and 20 from the aspirin alone group were collected. No significant differences were observed in biomarkers between patients receiving rivaroxaban plus aspirin and those receiving aspirin alone.ConclusionThere were no differences in coagulation or inflammatory biomarkers in patients with intermittent claudication treated with either rivaroxaban plus aspirin or aspirin alone.
No takes yet. Share an insight, caveat, or question.
Britto et al. (2025) conducted an RCT in Peripheral artery disease and intermittent claudication (n=36). Rivaroxaban plus aspirin vs. Aspirin 100 mg once daily alone was evaluated on Plasma levels of coagulation and inflammatory biomarkers at 24 weeks. Rivaroxaban plus aspirin did not significantly alter coagulation or inflammatory biomarkers compared to aspirin alone at 24 weeks in patients with intermittent claudication.
Synapse has enriched 10 related papers. Consider them for comparative context: